



OPEN ACCESS

EDITED BY

Kay Grobe,
University of Münster, Germany

REVIEWED BY

Neha S. Gandhi,
Queensland University of Technology,
Australia
María Eugenia De La Morena-Barrio,
University of Murcia, Spain

*CORRESPONDENCE

Weihua Jin,
jinweihua@zjut.edu.cn
Fuming Zhang,
zhangf2@rpi.edu
Robert J. Linhardt,
linhar@rpi.edu

SPECIALTY SECTION

This article was submitted to
Glycoscience,
a section of the journal
Frontiers in Molecular Biosciences

RECEIVED 27 May 2022

ACCEPTED 05 September 2022

PUBLISHED 19 September 2022

CITATION

Zhang W, Jin W, Pomin VH, Zhang F and
Linhardt RJ (2022), Interactions of
marine sulfated glycans with
antithrombin and platelet factor 4.
Front. Mol. Biosci. 9:954752.
doi: 10.3389/fmolb.2022.954752

COPYRIGHT

© 2022 Zhang, Jin, Pomin, Zhang and
Linhardt. This is an open-access article
distributed under the terms of the
[Creative Commons Attribution License](#)
(CC BY). The use, distribution or
reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

Interactions of marine sulfated glycans with antithrombin and platelet factor 4

Wenjing Zhang¹, Weihua Jin^{2,3*}, Vitor H. Pomin⁴,
Fuming Zhang^{2*} and Robert J. Linhardt^{2,5*}

¹Department of Endocrinology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China, ²Department of Chemical and Biological Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, United States, ³College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, China, ⁴Department of BioMolecular Sciences, The University of Mississippi, Oxford, MS, United States, ⁵Departments of Biological Science, Chemistry and Chemical Biology and Biomedical Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, United States

The molecular interactions of sulfated glycans, such as heparin, with antithrombin (AT) and platelet factor 4 (PF4) are essential for certain biological events such as anticoagulation and heparin induced thrombocytopenia (HIT). In this study, a library including 84 sulfated glycans (polymers and oligomers) extracted from marine algae along with several animal-originated polysaccharides were subjected to a structure-activity relationship (SAR) study regarding their specific molecular interactions with AT and PF4 using surface plasmon resonance. In this SAR study, multiple characteristics were considered including different algal species, different methods of extraction, molecular weight, monosaccharide composition, sulfate content and pattern and branching vs. linear chains. These factors were found to influence the binding affinity of the studied glycans with AT. Many polysaccharides showed stronger binding than the low molecular weight heparin (e.g., enoxaparin). Fourteen polysaccharides with strong AT-binding affinities were selected to further investigate their binding affinity with PF4. Eleven of these polysaccharides showed strong binding to PF4. It was observed that the types of monosaccharides, molecular weight and branching are not very essential particularly when these polysaccharides are oversulfated. The sulfation levels and sulfation patterns are, on the other hand, the primary contribution to strong AT and PF4 interaction.

KEYWORDS

antithrombin, carbohydrate-protein interactions, heparin, platelet factor 4, sulfated glycans, surface plasmon resonance

Introduction

Antithrombin (AT) regulates the proteolytic activity of procoagulant proteases in both the intrinsic and extrinsic coagulation pathways and cause the anti-inflammatory signaling response through binding with syndecans-4 heparan sulfate proteoglycans (HSPGs) of different vascular endothelial cells (Carrell et al., 1997; Olson, Richard et al., 2010; Rezaie and Giri, 2020). Moreover, HSPGs with low affinity for AT stimulate potent proapoptotic and antiangiogenic activities (Rezaie and Giri, 2020).

Heparin induced thrombocytopenia (HIT) is a severe fatal immunothrombotic disorder resulting from the clinical application of heparin. Platelet factor 4 (PF4) is associated with HIT through a pathway involving the initial binding of PF4 to heparin to form heparin-PF4 neoepitope. This is followed by the production of anti-PF4-heparin antibodies and immunoglobulin G (IgG)-heparin-PF4 immune complex cluster, and finally platelet activation and aggregation (Zhang, Datta, Dordick, and Linhardt, 2020). The results of fluorescence spectroscopy indicated that two molecules of PF4 can bind to one molecule of high molecular weight (HMW) heparin and its avidity for HMW highly active heparin appeared to be at least 10- to 100- times greater than antithrombin's avidity (Jordan, Favreau, Braswell and Rosenberg, 1982). Moreover, the carboxy-terminal amino acids of PF4 are critically important for binding to natural and synthetic GAGs (Loscalzo, Melnick, and Handin, 1985).

Heparin is a linear sulfated glycosaminoglycan, consisting mainly of disaccharide units 1→4 linked of *N*-sulfo, 6-*O*-sulfo α -D-glucosamine (GlcNS6S) and 1→4 linked 2-*O*-sulfo α -L-iduronic acid (IdoA2S) units. These trisulfated disaccharides can be accompanied with small amounts of *N*-acetyl α -D-glucosamine (GlcNAc) or *N*-sulfo, 3-*O*-sulfo, 6-*O*-sulfo α -D-glucosamine (GlcNS3S6S) disaccharide units. A specific pentasaccharide sequence (GlcNAc/NS6S-GlcA-GlcNS3S6S-IdoA2S-GlcNS6S) binds and activates AT resulting in heparin's anticoagulant activity. The first trisaccharide unit (GlcNAc/NS6S-GlcA-GlcNS3S6S) is considered the initiator in the recognition of polysaccharide by the protein (Desai et al., 1998; Elli et al., 2020).

Other sulfated polysaccharides, as potential heparin mimetics, can be obtained in abundance from marine sources such as seaweeds. Seaweeds are taxonomically classified into three groups, green algae, red algae and brown algae. Polysaccharides from green algae contain two major types of sulfated polysaccharides, sulfated xylo-galacto-arabinans and sulfated xylo-glucurono-rhamnans (Jin, Zhang, Liang, and Zhang, 2016). Red algae have three major types of polysaccharides, the neutral polysaccharide agar, sulfated polysaccharide carrageenan and an agar-carrageenan hybrid. Brown algae contain the neutral polysaccharide laminaran, alginate and fucoidan. Fucoidans, a family of heteropolysaccharides, mainly consist of sulfated fucan, sulfated galactofucan and sulfated glucuronomannan derivatives (Deniaud-Bouet, Hardouin, Potin, Kloareg, and Herve, 2017). However, not all sulfated polysaccharides, like

heparin, exhibit anticoagulant and/or antithrombotic activity (Pomin, 2014a, 2014b, 2015; Pomin and Mourão, 2014; Vasconcelos et al., 2018; Pomin et al., 2019). Fucosylated chondroitin sulfate has strong anticoagulant and antithrombotic activity, and the fucose pyranose branch and sulfation patterns are critical for this activity (Liu, Zhang, and Linhardt, 2009; Chen et al., 2013). A 2-*O*-sulfated fucose residue adversely impacts activity while 2-*O*-sulfated galactose and 4-*O*-sulfated fucose residues increase anticoagulation (Vasconcelos et al., 2018). Moreover, a high molecular weight is important for anticoagulation activity.

The anticoagulant activities of marine sulfated polysaccharides mainly result from their interaction with natural plasma serine proteases inhibitors (serpins), such as AT and heparin cofactor II (HC II) (Pomin, 2012). Marine sulfated polysaccharides inhibit coagulation through two distinct mechanisms. The first relies on the allosteric effects of serpins, particularly for HC II, and the second happens through a template mechanism, in which marine sulfated polysaccharides act as a "molecular bridge," bringing serine protease and serpin together (Pomin, 2012).

Several series of oligosaccharides, polysaccharides and their derivatives were prepared in this work to find the candidates for antithrombotic treatments and antidotes to low molecular heparins. The interaction of marine algae polysaccharide with AT and PF4 were determined using surface plasmon resonance (SPR). The results obtained here were used to systematically analyze the structure-activity relationship found in the resultant intermolecular complexes made between marine sulfated glycans and AT/PF4, to identify specific characteristics that will contribute to the best molecular interactions.


Materials and methods

Materials

Heparin was purchased from Celsus Laboratories (Cincinnati, OH). Enoxaparin from Sandoz was generously provided by Dr. Jawed Fareed in Loyola University Medical Center (Maywood, IL). AT and human PF4 were purchased from Hyphen BioMed (Neuville-sur-Oise, France). Streptavidin (SA) sensor chips and HBS-EP buffer were purchased from Cytiva.

Preparation of oligosaccharides, polysaccharides and their derivatives

Marine algae oligosaccharides, polysaccharides and their derivatives together with several animal-originated polysaccharides were prepared based on the previous studies (Ciancia et al., 2005; Wang et al., 2010; Anastuyuk et al., 2012; Jin et al., 2012, Jin et al., 2013, Jin et al., 2017, Jin et al., 2018a, Jin



Scheme 1

The flow chart of sulfated glycans preparation.

et al., 2018b, Jin et al., 2019, Jin et al., 2020a, Jin et al., 2020b, Jin et al., 2020c, Jin et al., 2020d; Rodriguez-Jasso et al., 2013; Menshova et al., 2015; Shevchenko et al., 2015; Wu et al., 2015). They were summarized in Scheme 1, Table 1 with proposed structures in Figure 1 and more details can be found in Supplementary Table S1 (Supplementary data 1).

Surface plasmon resonance analysis

Biotinylated heparin was immobilized on a streptavidin (SA) chip to prepare a heparin chip (Zhang et al., 2019). In brief, 20 μ L solution of biotinylated heparin (0.1 mg/ml) in HBS-EP + buffer (0.01 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 0.15 M NaCl, 3 mM EDTA, 0.05% surfactant P20, pH 7.4) was injected over flow cell 2 (FC2), 3 (FC3) and 4 (FC4) of the SA chips at a flow rate of 10 μ L/min. The successful immobilization of GAGs was confirmed by the observation of a ~200 resonance unit (RU) increase in the sensor chip. The control flow cell (FC1) was prepared by 1 min injection with saturated biotin.

Kinetic measurements of interactions between AT-heparin and PF4-heparin were performed. Briefly, 90 μ L different concentrations of AT and PF4 diluted in HBS-EP buffer were injected over to the heparin chip at a flow rate of 30 μ L/min. After each run, there was a 3 min dissociation time and a 1 min regeneration time using 2 M NaCl for AT and 10 mM glycine-

HCl pH 2.5 buffer and 2 M NaCl for PF4. The response (RU) was monitored as a function of time (sensorgram) at 25°C.

Solution competition SPR was used to examine the relative binding affinity of sulfated glycans with AT or PF4. Protein (AT or PF4) was pre-mixed with different sulfated glycans before injection into the heparin chip. Once the active binding sites on AT or PF4 were occupied by glycan in solution, its binding to the surface-immobilized heparin decreased, resulting in a reduction of signal (RU) in a concentration-dependent fashion. Competition study was performed by injecting 90 μ L mixtures of 1 μ M glycans, including enoxaparin, with 250 nM of AT or 25 nM of PF4 for comparing the binding abilities of different sulfated glycans. For IC₅₀ measurements, five different concentrations of glycan samples (from 0.5 to 1,000 nM), including enoxaparin, were premixed with 250 nM of AT or 25 nM of PF4, then injected to the heparin chip to test the inhibition on heparin-AT, or heparin-PF4 interaction. Other protocols were performed as described above.

Results and discussion

Kinetics measurements of antithrombin and PF4 interaction with heparin

It is well known that the molecular interactions of AT and PF4 with heparin are essential factors for heparin

TABLE 1 Samples and their abbreviation in this study.

NO	Abbreviation	Structural type	Characteristics
1	SJ	Fucoidan from <i>Saccharina japonica</i>	Crude polysaccharide obtained by hot water extraction
2	SJ-W	heteropolysaccharides	0.5 M NaCl fraction from SJ using anion exchange chromatography
3	SJ-I	Sulfated galactofucan	1.0 M NaCl fraction from SJ using anion exchange chromatography
4	SJ-S	Sulfated galactofucan	2.0 M NaCl fraction from SJ using anion exchange chromatography
5	SJ-D	Low molecular weight Fucoidan	Degraded from SJ
6	SJ-D-W	heteropolysaccharides	0.5 M NaCl fraction from SJ-D using anion exchange chromatography
7	SJ-D-I	Sulfated galactofucan	1.0 M NaCl fraction from SJ-D using anion exchange chromatography
8	SJ-D-S	Sulfated galactofucan	2.0 M NaCl fraction from SJ-D using anion exchange chromatography
9	SJ-D-W-H	heteropolysaccharides	High molecular weight fraction obtained by autohydrolysis from SJ-D-W
10	SJ-D-W-L	heteropolysaccharides	Low molecular weight fraction obtained by autohydrolysis from SJ-D-W
11	SJ-D-I-H	Sulfated galactofucan	High molecular weight fraction obtained by autohydrolysis from SJ-D-I
12	SJ-D-I-L	Sulfated galactofucan	Low molecular weight fraction obtained by autohydrolysis from SJ-D-I
13	SJ-D-S-H	Sulfated galactofucan	High molecular weight fraction obtained by autohydrolysis from SJ-D-S
14	SJ-D-S-L	Sulfated galactofucan	Low molecular weight fraction obtained by autohydrolysis from SJ-D-S
15	SJ-I-PS	Sulfated galactofucan	Oversulfation of SJ-I
16	SJ-S-PS	Sulfated galactofucan	Oversulfation of SJ-S
17	SJ-D-I-PS	Sulfated galactofucan	Oversulfation of SJ-D-I
18	SJ-D-S-PS	Sulfated galactofucan	Oversulfation of SJ-D-S
19	SJ-I-DS	Sulfated galactofucan	Desulfation of SJ-I
20	SJ-S-DS	Sulfated galactofucan	Desulfation of SJ-S
21	SJ-D-I-S	Sulfated galactofucan	Desulfation of SJ-D-I
22	SJ-D-S-DS	Sulfated galactofucan	Desulfation of SJ-D-S
23	SJ-100K	Fucoidan	Fraction obtained by using 100 K cut-off from 0.2 M HCOOH degradation of SJ
24	SJ-50K	Fucoidan	Fraction obtained by using 50 K cut-off from 0.2 M HCOOH degradation of SJ
25	SJ-30K	Fucoidan	Fraction obtained by using 30 K cut-off from 0.2 M HCOOH degradation of SJ
26	SJ-10K	Fucoidan	Fraction obtained by using 10 K cut-off from 0.2 M HCOOH degradation of SJ
27	SJ-3K	Fucoidan	Fraction obtained by using 3 K cut-off from 0.2 M HCOOH degradation of SJ
28	SJ-GX-1	Fucoidan	Dilute acid-sensitive fraction obtained by acid degradation of SJ
29	SJ-GX-2	Fucoidan	Acid-sensitive fraction obtained by acid degradation of SJ
30	SJ-GX-3	Fucoidan	Acid-stable fraction obtained by acid degradation of SJ
31	SJ-D-W-GX-1	Fucoidan	Dilute acid-sensitive fraction obtained by acid degradation of SJ-D-W
32	SJ-D-W-GX-2	Fucoidan	Acid-sensitive fraction obtained by acid degradation of SJ-D-W
33	SJ-D-W-GX-3	Fucoidan	Acid-stable fraction obtained by acid degradation of SJ-D-W
34	G2	Glucuronomannan-dimer	β -D-glucuronosyluronic acid-(1 \rightarrow 2)- α /D-mannose
35	G4	Glucuronomannan-tetramer	β -D-glucuronosyluronic acid-(1 \rightarrow 2)- α -D-mannose-(1 \rightarrow 4) - β -D-glucuronosyluronic acid-(1 \rightarrow 2)- α /D-mannose
36	G6	Glucuronomannan-hexamer	β -D-glucuronosyluronic acid-(1 \rightarrow 2)- α -D-mannose-(1 \rightarrow 4) - β -D-glucuronosyluronic acid-(1 \rightarrow 2)- α -D-mannose-(1 \rightarrow 4) - β -D-glucuronosyluronic acid-(1 \rightarrow 2)- α /D-mannose
37	Gn	glucuronomannan	Poly (β -D-glucuronosyluronic acid-(1 \rightarrow 2)- α -D-mannose-(1 \rightarrow 4), alternating)
38	STW	Fucoidan from <i>Sargassum thunbergii</i>	Crude polysaccharide obtained by hot water extraction
39	STA	Fucoidan from <i>Sargassum thunbergii</i>	Crude polysaccharide obtained by acid extraction
40	STJ	Fucoidan from <i>Sargassum thunbergii</i>	Crude polysaccharide obtained by alkali extraction
41	EP	sulfated glucurono-xylo-rhamnan	Crude polysaccharide obtained by hot water extraction
42	STW-W	heteropolysaccharides	0.5 M NaCl fraction from STW using anion exchange chromatography
43	STW-I	Sulfated galactofucan (Mainly)	1.0 M NaCl fraction from STW using anion exchange chromatography
44	STW-S	Sulfated galactofucan	2.0 M NaCl fraction from STW using anion exchange chromatography

(Continued on following page)

TABLE 1 (Continued) Samples and their abbreviation in this study.

NO	Abbreviation	Structural type	Characteristics
45	STA-W	heteropolysaccharides	0.5 M NaCl fraction from STA using anion exchange chromatography
46	STA-I	Sulfated galactofucan (Mainly)	1.0 M NaCl fraction from STA using anion exchange chromatography
47	STA-S	Sulfated galactofucan	2.0 M NaCl fraction from STA using anion exchange chromatography
48	STJ-W	heteropolysaccharides	0.5 M NaCl fraction from STJ using anion exchange chromatography
49	STJ-I	Sulfated galactofucan	1.0 M NaCl fraction from STJ using anion exchange chromatography
50	STJ-S	Sulfated galactofucan	2.0 M NaCl fraction from STJ using anion exchange chromatography
51	EP-W	sulfated glucurono-xylo-rhamnan	0.3 M NaCl fraction from EP using anion exchange chromatography
52	EP-I	sulfated glucurono-xylo-rhamnan	1.0 M NaCl fraction from EP using anion exchange chromatography
53	EP-S	sulfated glucurono-xylo-rhamnan	2.0 M NaCl fraction from EP using anion exchange chromatography
54	STW-100K	Fucoidan	Fraction obtained by using 100 K cut-off from 0.2 M HCOOH degradation of STW
55	STW-50K	Fucoidan	Fraction obtained by using 50 K cut-off from 0.2 M HCOOH degradation of STW
56	STW-30K	Fucoidan	Fraction obtained by using 30 K cut-off from 0.2 M HCOOH degradation of STW
57	STW-10K	Fucoidan	Fraction obtained by using 10 K cut-off from 0.2 M HCOOH degradation of STW
58	STW-3K	Fucoidan	Fraction obtained by using 3 K cut-off from 0.2 M HCOOH degradation of STW
59	STA-100K	Fucoidan	Fraction obtained by using 100 K cut-off from 0.2 M HCOOH degradation of STA
60	STA-50K	Fucoidan	Fraction obtained by using 50 K cut-off from 0.2 M HCOOH degradation of STA
61	STA-30K	Fucoidan	Fraction obtained by using 30 K cut-off from 0.2 M HCOOH degradation of STA
62	STA-10K	Fucoidan	Fraction obtained by using 10 K cut-off from 0.2 M HCOOH degradation of STA
63	STA-3K	Fucoidan	Fraction obtained by using 3 K cut-off from 0.2 M HCOOH degradation of STA
64	STJ-100K	Fucoidan	Fraction obtained by using 100 K cut-off from 0.2 M HCOOH degradation of STJ
65	STJ-50K	Fucoidan	Fraction obtained by using 50 K cut-off from 0.2 M HCOOH degradation of STJ
66	STJ-30K	Fucoidan	Fraction obtained by using 30 K cut-off from 0.2 M HCOOH degradation of STJ
67	STJ-10K	Fucoidan	Fraction obtained by using 10 K cut-off from 0.2 M HCOOH degradation of STJ
68	STJ-3K	Fucoidan	Fraction obtained by using 3 K cut-off from 0.2 M HCOOH degradation of STJ
69	EP-100K	sulfated glucurono-xylo-rhamnan	Fraction obtained by using 100 K cut-off from 0.2 M HCOOH degradation of EP
70	EP-50K	sulfated glucurono-xylo-rhamnan	Fraction obtained by using 50 K cut-off from 0.2 M HCOOH degradation of EP
71	EP-30K	sulfated glucurono-xylo-rhamnan	Fraction obtained by using 30 K cut-off from 0.2 M HCOOH degradation of EP
72	EP-10K	sulfated glucurono-xylo-rhamnan	Fraction obtained by using 10 K cut-off from 0.2 M HCOOH degradation of EP
73	EP-3K	sulfated glucurono-xylo-rhamnan	Fraction obtained by using 3 K cut-off from 0.2 M HCOOH degradation of EP
74	Enoxaparin	Enoxaparin	Purchased from Teva Parenteral Medicines, Inc
75	LC	λ -carrageenan	Purchased from Millipore Sigma
76	IC	iota carrageenan	Purchased from Millipore Sigma
77	KC	kappa carrageenan	Purchased from Millipore Sigma
78	Agar	Agar	Purchased from Millipore Sigma
79	Des-H	Desulfated heparin	Provided by Robert J. Linhardt's Lab
80	Heparosan	Heparosan	Provided by Robert J. Linhardt's Lab
81	SF	Sulfated fucan	SF, provided by Vitor H Pomin, was extracted from <i>Lytechinus variegates</i> (sea urchin)
82	LA-PS	Sulfated laminaran	Oversulfation of laminaran
83	LA	Laminaran from <i>Sargassum thunbergii</i>	Water fraction from STW using anion exchange chromatography
84	LAO	Glucoglucuronan	Oxidized laminarin

anticoagulant and heparin induced thrombocytopenia (HIT). In current study, SPR was applied to measure the binding kinetics and affinity of AT and PF4 interaction with heparin using a sensor chip with immobilized heparin. Sensorgrams of AT and PF4 interactions with heparin are shown in Figure 2. Binding kinetics (i.e., association rate constant: ka ;

dissociation rate constant: kd) and affinity (i.e., $K_D = kd/ka$) were calculated by globally fitting the sensorgrams using 1: 1 Langmuir binding model. AT-heparin interaction: $ka = 1.2 \times 10^5$ 1/Ms, $kd = 4.4 \times 10^{-4}$ 1/s, and $K_D = 3.6$ nM; PF4-heparin interaction: $ka = 9.6 \times 10^4$ 1/Ms, $kd = 1.1 \times 10^{-4}$ 1/s, and $K_D = 1.2$ nM.




FIGURE 1

Proposed primary structures of polysaccharides used in this study.




FIGURE 2

(A) SPR sensorgram of AT-heparin interaction. Concentrations of AT (from top to bottom) were 1,000, 500, 250, 125, and 63 nM, respectively. The AT-heparin-binding kinetics were determined by global fitting the curves to a 1:1 biomolecular reaction model (black lines) using the BIA evaluation software 4.01. (B) SPR sensorgram of PF4-heparin interaction. Concentrations of PF4 (from top to bottom) were 100, 50, 25, 12.5, and 6.3 nM, respectively. The PF4-heparin binding kinetics were determined by globally fitting the curves to a 1:1 biomolecular reaction model (black lines) using the BIAevaluation software 4.0.1.




FIGURE 3

The binding abilities to AT (250 nM) premixed with different MW of polysaccharides (1 μ M) on a heparin chip. (A) SJ and its fractions; (B) low molecular weight SJ-D and its fractions. All bar graphs with standard deviations were based on triplicate experiments. * $p < 0.05$, ** $p < 0.01$ compared with control.

Surface plasmon resonance competition study on polysaccharides fractionated by anion exchange chromatography on heparin chip binding to antithrombin

The relative binding affinities to AT of crude polysaccharide from brown algae *Saccharina japonica* (SJ) and its derivatives were determined by SPR. SJ-S is a sulfated galactofucan based on previous studies (Jin, et al., 2020d). SJ-S, having the highest negative charge, showed the strongest inhibition of binding (78% vs. 87% enoxaparin) (Figure 3A), indicating that SJ-S was an active component. SJ-D was prepared to evaluate the impact of molecular weight on AT interaction. The inhibitory activities of SJ and SJ-D were similar, suggesting that molecular weight of these two samples did not influence their competitive binding ability. In contrast, low molecular weight fractions (SJ-D-W, SJ-D-I, and SJ-D-S) showed lower competitive binding to AT (Figure 3B) than the corresponding higher molecular weight fractions, suggesting that molecular weight is important factor to bind AT.

Competition study on modified polysaccharides (mainly sulfated galactofucans) on heparin chip binding to antithrombin

The AT-binding polysaccharides are sulfated galactofucan based on the results of heparin competition studies. Autohydrolysis, desulfation and oversulfation were performed to study the effects of sulfation level, sulfation pattern and

molecular weight. The H-type fractions, obtained by autohydrolysis, display similar inhibitory activities as the corresponding unfractionated material (Figure 4A). C2-selective desulfation of fucopyranose (Fuc) and degradation happen during the process of autohydrolysis (Ciancia et al., 2005; Pomin et al., 2005; Anastuyk et al., 2012; Rodriguez-Jasso et al., 2013; Menshova et al., 2015; Shevchenko et al., 2015; Wu et al., 2015). This suggests that sulfation at the C2 of Fuc residues is not crucial for AT-binding. Desulfation lowered AT-binding while oversulfation increased AT-binding of low molecular weight fractions (SJ-D-I and SJ-D-S) (Figure 4B). Oversulfation of SJ-I and SJ-S had little impact on AT-binding. These results indicate that molecular weight and sulfation are necessary for the AT-binding of sulfated galactofucans.

Competition study on modified polysaccharides (glucuronomannan derivatives) on heparin chip binding to antithrombin

Formic acid (0.2 M) was used to degrade SJ and separated by five molecular weight cut off (MWCO) membranes (100, 50, 30, 10 and 3 K). The larger molecular weight fractions showed stronger binding to AT, suggesting that acid stable fractions might show the strongest binding to AT (Figure 5). According to previous studies (Jin et al., 2012; Wu et al., 2015; Deniaud-Bouet et al., 2017), acid stable fractions were glucuronomannan derivatives. SJ-GX-3 displayed stronger inhibition of binding than SJ-GX-1 and SJ-GX-2, which confirmed that the acid stable fractions showed the best competition for heparin




FIGURE 4

The binding abilities to AT (250 nM) premixed with different chemical modified polysaccharides (1 μ M) on a heparin chip. (A) Polysaccharides obtained from autohydrolysis and (B) desulfated or oversulfated polysaccharides. All bar graphs with standard deviations were based on triplicate experiments. * $p < 0.05$, ** $p < 0.01$ compared with control.

binding to AT. However, it was disappointing that the glucuronomannan (Gn) with 7.0 kDa showed low AT-binding, which might be best based on its molecular weight. In summary, we hypothesize that polysaccharides that elute from ion-exchange resin with 2 M NaCl or are retained with 100 kDa cut-off exhibit the strongest binding to AT.

Competition study on different polysaccharides on heparin chip binding to antithrombin

The AT-binding affinity of STW (70%) was like STJ's (70%) and larger than STA's (46%) (Figure 6A). These results can be explained by degradation and desulfation that occurs under conditions of acidic extraction. EP showed no AT-binding, suggesting that the extraction methods and different algae sulfated polysaccharides impacted binding.

STW, STA, STJ, and EP were separated by anion-exchange chromatography and MWCO membranes to confirm the impact of size and charge on AT-binding. Thirty-two fractions were obtained and determined the binding ability to bind to AT. STW-S (71%) had the strongest inhibition of binding, followed by STW-I and STW-W showed the weakest inhibition of binding (Figure 6B). Fractions of STJ showed similar pattern, which is STJ-S (78%) > STJ-I > STJ-W. However, the AT-binding affinity of STJ's fractions and EP's fractions showed different patterns, which were EP-I > EP-W > EP-S \approx EP and STA \approx STA-W > STA-S > STA-I, respectively.

We suggest that while elution from an anion exchange resin with 2 M NaCl, corresponds to the fraction with the highest charge, this fraction does not always exhibit the strongest AT-binding affinity. The AT-binding affinity of fractions obtained by MWCO membranes was next determined (Figure 6C). Components retained with 100 kDa cut-off exhibited the strongest binding to AT except for the EP fractions. This




FIGURE 5

The binding abilities to AT (250 nM) premixed with different glycans (1 μ M) on a heparin chip. (A) glycans derived from MWCO membranes; (B) fractions obtained from acid degradation; (C) glucuronomannan (Gn) and its oligomers. All the bar graphs with standard deviations were based on triplicate experiments. * $p < 0.05$, ** $p < 0.01$ compared with control.

might be explained by the different behavior of different types of polysaccharides. Polysaccharides from *S. japonica* and *S. thunbergii* belonged to fucose-containing sulfated polysaccharides (FCSPs) while polysaccharides from *E. prolifera* belong to rhamnose-containing sulfated polysaccharides. These data show that FCSPs components retained with 100 kDa cut-off showed the strongest AT-binding.

IC₅₀ measurements of polysaccharides inhibiting antithrombin interaction with heparin on chip

Based on the above results, we propose that fractions eluting with 2 M NaCl and retained with 100 and 50 kDa cut-off showed the strongest AT-binding. Therefore, we determined the 50% inhibition concentration (IC₅₀) of five S-type fractions, 100K-type fractions and 50K-type fractions (Table 2). The IC₅₀ of the fractions derived from STA were larger than fractions obtained

from STJ and STW, suggesting that acid-treated decrease AT-binding activity. In addition, polysaccharides from different algae had different acid-sensitivity, which was confirmed by the comparison of SJ-100K and STW-100K or SJ-50K and STW-50K fractions.

Higher molecular weight fractions showed lower IC₅₀ values, which was also consistent with results for SJ-D-S (The IC₅₀ was 5.7 μ M). It is interesting to note that the IC₅₀ of EP-S, EP-100K and EP-50K were $\geq 10 \mu$ M while the IC₅₀ of EP-I was 134 nM value. There are 11 sulfated glycans having lower IC₅₀ values in Table 2 than that for the low molecular weight heparin, enoxaparin (~444 nM). Among these, the IC₅₀ values of SJ-S, STJ-S, STW-100K, STJ-100K, LA-PS, STW-50K and LC were below 100 nM. The kinetic measurements of the interaction of polysaccharides with AT were determined by solution-based affinities (K_i), using the equation: $K_i = IC_{50}/(1 + [C]/K_D)$, where [C] is the concentration of AT (250 nM) used in the competition SPR and the dissociation constant (K_D) for heparin and AT was 151 nM (Zhao, Kong, Zhang, and Linhardt, 2018; Jin, et al.,




TABLE 2 IC₅₀ values of sulfated glycans on inhibiting AT binding to heparin (on chip surface).

Samples	IC ₅₀ (nM)	Samples	IC ₅₀ (nM)	Samples	IC ₅₀ (nM)
SJ-S	9	SJ-100K	2,948	SJ-50K	4,314
STW-S	103	STW-100K	47	STW-50K	89
STA-S	740	STA-100K	117	STA-50K	555
STJ-S	41	STJ-100K	37	STJ-50K	119
EP-S	>1,000	EP-100K	>1,000	EP-50K	>1,000
EP-I	134	SJ-GX-3	1,000	SJ-D-S	5,675
SF	1840	LA-PS	86	LC	9
Enoxaparin	444				

TABLE 3 IC₅₀ values of sulfated glycans on inhibiting PF4 binding to heparin (on chip surface).

Samples	IC ₅₀ (nM)	Samples	IC ₅₀ (nM)	Samples	IC ₅₀ (nM)
STW-S	4.0	STW-100K	10.8	STW-50K	16.3
STA-S	1.1	STA-100K	4.8	STA-50K	27.1
STJ-S	1.5	STJ-100K	2.5	STJ-50K	10.4
SJ-S	1.0	EP-I	>1,000	LC	2.3
Enoxaparin	12.6	SF	1.0	LA-PS	1.8




FIGURE 7

The binding abilities to AT of different polysaccharides on a surface heparin chip. Concentrations of AT and sulfated glycan samples were 250 nM and 1 μ M, respectively. All bars with standard deviations were based on triplicate experiments. * $p < 0.05$, ** $p < 0.01$ compared with control.

2020c). It was found that the smallest K_i of three were SJ-S (3 nM), STJ-100K (14 nM) and STJ-S (15 nM). The K_i of EP-I was 50 nM.

SJ-S was a sulfated galactofucan, STJ-100K was a sulfated glucuronomannan derivative and EP-I was a sulfated xylo-glucuronorhamnan (Figure 1). By examining heparin, we found that sulfation was required as desulfated heparin (Des-H) and the heparin precursor, (heparosan), showed no AT-binding (Figure 7). In addition, we found that the type of monosaccharides comprising the polysaccharide were unimportant for AT-binding, which was also confirmed by the result obtained over sulfated laminarin (LA-PS) (Figure 7). It is harder to draw a firm conclusion about the importance of glucuronic acid (GlcA) residues for AT-binding. Oxidized laminarin (LAO) showed a weak inhibition of binding (Figure 7). Therefore, GlcA might not be essential, particularly if most GlcA residues were are sulfated. It has been reported that the critical glucuronic acid in the first trisaccharides of the AT-binding site can be replaced by 2-O-sulfated iduronic acid (Elli et al., 2020).

The binding abilities of five types of sulfated galactans, agar (containing no sulfation), kappa-carrageenan (one sulfate per disaccharide unit), iota-carrageenan (two sulfates per disaccharide unit) and lambda-carrageenan (three sulfates per disaccharide unit) were next determined. These data suggest that the types of monosaccharide residues present had no impact on AT-binding and that binding increased with the increasing content of sulfate. A linear sulfated fucan (2.5 sulfates per disaccharide unit, SF) was also used to determine the binding affinity. The IC_{50} of SF (1840 nM) was higher than SJ-S (9 nM), suggesting that branching was important.

IC_{50} measurements of polysaccharides inhibiting PF4 interaction with heparin on chip

It is known that 0.2%–3% patients show HIT when treated with heparin, which can lead to life threatening thrombosis and clinical symptoms (Fischer, 2001). Therefore, it is important to understand the binding affinity of anticoagulants to PF4. The IC_{50} of 14 candidates in inhibiting PF4 binding to heparin were determined in Table 3. The IC_{50} of enoxaparin was 12.6 nM and only three candidates (EP-I, STW-50K and STA-50K) showed higher IC_{50} . Compared 100K-type fractions with 50K-type fractions, it was concluded that low molecular weight fractions had lower binding abilities to PF4. It was noteworthy that EP-I exhibited the lowest binding affinity for among the candidates and the IC_{50} of EP-I was larger than 1 μ M.

Conclusion

A systematic study was performed to study the structure-activity relationship between marine algae sulfated polysaccharides and AT and PF4 binding to find the candidates for antithrombotic treatments and antidotes to low molecular heparins. Comparing SJ with its fractions, it was found that sulfated galactofucan showed the strongest inhibitory activity. The results on the binding abilities of samples with oversulfation, desulfation and desulfation at the C2 of Fuc residues suggested that the sulfation level and proper sulfation pattern are of primary importance on AT and PF4 binding in

most cases. SJ and SJ-D had similar binding abilities to AT while SJ-100K, SJ-50K, SJ-30K, SJ-10K, and SJ-3K had different binding abilities, indicating that molecular weight may be not a major factor, which was confirmed by the results of other fractions derived from MWCO membranes. The AT-binding affinities of four crude polysaccharides (STW, STA, STJ, and EP) showed that the extraction methods and different algae sulfated polysaccharides could impact the binding abilities. Simply binding to AT does not necessarily mean that antithrombin becomes activated as a protease inhibitor. The target protease is thrombin (rather than Factor Xa) as previous studies (Pomin, 2012) demonstrated that sulfated marine glycans are primarily active as anticoagulants by direct binding to the serine protease thrombin or by indirectly binding to HC II, a serine protease inhibitor acting on thrombin. Sulfated laminaran, carrageenan, sulfated fucan, sulfated galactofucans, sulfated glucuronomannan derivatives and sulfated xylo-glucuronorhamnan showed strong inhibitory activities, suggesting that the types of monosaccharides present are unimportant, particularly when these polysaccharides are oversulfated. Finally, a linear sulfated fucan from (sea urchin) *Lytechinus variegatus* and other branched sulfated galactofucans had similar IC_{50} values on inhibiting PF4 binding to heparin, indicating branching is not a major factor for polysaccharide binding.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

Author contributions

Conceptualization, WZ, WJ, and FZ; methodology, WZ, WJ, and FZ; formal analysis, WZ, and WJ; resources, VP; original draft preparation, WZ, and WJ; review and editing, FZ and RL;

References

- Anastyuk, S. D., Imbs, T. I., Shevchenko, N. M., Dmitrenok, P. S., and Zvyagintseva, T. N. (2012). ESIMS analysis of fucoidan preparations from *Costaria costata*, extracted from alga at different life-stages. *Carbohydr. Polym.* 90 (2), 993–1002. doi:10.1016/j.carbpol.2012.06.033
- Carrell, R., Skinner, R., Jin, L., and Abrahams, J. P. (1997). Structural mobility of antithrombin and its modulation by heparin. *Thromb. Haemost.* 78 (1), 516–519. doi:10.1055/s-0038-1657579
- Chen, S., Li, G., Wu, N., Guo, X., Liao, N., Ye, X., et al. (2013). Sulfation pattern of the fucose branch is important for the anticoagulant and antithrombotic activities of fucosylated chondroitin sulfates. *Biochim. Biophys. Acta* 1830 (4), 3054–3066. doi:10.1016/j.bbagen.2013.01.001
- Ciancia, M., Satob, Y., Nonamic, H., Cerezod, A. S., Erra-Balsellsd, R., and Matulewicz, M. C. (2005). Autohydrolysis of a partially cyclized mu/nu-carrageenan and structural

funding acquisition, VP, RL, WZ, WJ, and FZ. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by the National Natural Science Foundation of China (No. 41906095 to WZ); the Zhejiang Provincial Natural Science Foundation of China (No. LY19D060006 to WJ.); the National Institutes of Health (NIH) Grants DK111958, AG062344 and GlycoMIP a National Science Foundation Materials Innovation Platform funded through Cooperative Agreement DMR-1933525 to FZ and RL; NIH/NIGMS 1P20GM130460-01A1 sub-project 7936, NIH/NINDS 1R03NS110996-01A1, AACP 2019 New Investigator Award, and University of Mississippi to VP.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fmolb.2022.954752/full#supplementary-material>

elucidation of the oligosaccharides by chemical analysis, NMR spectroscopy and UV-MALDI mass spectrometry. *Arkivoc* 2005, 319–331.

Deniaud-Bouet, E., Hardouin, K., Potin, P., Kloareg, B., and Herve, C. (2017). A review about Brown algal cell walls and fucose-containing sulfated polysaccharides: Cell wall context, biomedical properties and key research challenges. *Carbohydr. Polym.* 175, 395–408. doi:10.1016/j.carbpol.2017.07.082

Desai, U. R., Petitou, M., Björk, I., and Olson, S. T. (1998). Mechanism of heparin activation of antithrombin. Role of individual residues of the pentasaccharide activating sequence in the recognition of native and activated states of antithrombin. *J. Biol. Chem.* 273 (13), 7478–7487. doi:10.1074/jbc.273.13.7478

Elli, S., Stancanelli, E., Wang, Z., Petitou, M., Liu, J., and Guerrini, M. (2020). Degeneracy of the antithrombin binding sequence in heparin: 2-O-sulfated

- iduronic acid can replace the critical glucuronic acid. *Chemistry* 26 (51), 11814–11818. doi:10.1002/chem.202001346
- Fischer, K. G. (2001). Mechanism and clinical presentation of heparin-induced thrombocytopenia. *Hemodial. Int.* 5 (1), 74–80. doi:10.1111/hdi.2001.5.1.74
- Jin, W., He, X., Wu, W., Bao, Y., Wang, S., Cai, M., et al. (2020a). Structural analysis of a glucogluconan derived from laminarin and the mechanisms of its anti-lung cancer activity. *Int. J. Biol. Macromol.* 163, 776–787. doi:10.1016/j.ijbiomac.2020.07.069
- Jin, W., He, X., Zhu, J., Fang, Q., Wei, B., Sun, J., et al. (2020b). Inhibition of glucuronomannan hexamer on the proliferation of lung cancer through binding with immunoglobulin G. *Carbohydr. Polym.* 248, 116785. doi:10.1016/j.carbpol.2020.116785
- Jin, W. H., Wang, J., Jiang, H., Song, N., Zhang, W. J., and Zhang, Q. B. (2013). The neuroprotective activities of heteropolysaccharides extracted from *Saccharina japonica*. *Carbohydr. Polym.* 97 (1), 116–120. doi:10.1016/j.carbpol.2013.04.055
- Jin, W. H., Wang, J., Ren, S. M., Song, N., and Zhang, Q. B. (2012). Structural analysis of a heteropolysaccharide from *Saccharina japonica* by electrospray mass spectrometry in tandem with collision-induced dissociation tandem mass spectrometry (ESI-CID-MS/MS). *Mar. Drugs* 10 (10), 2138–2152. doi:10.3390/md10102138
- Jin, W., Jiang, D., Zhang, W., Wang, C., Xia, K., Zhang, F., et al. (2020c). Interactions of fibroblast growth factors with sulfated galactofucan from *Saccharina japonica*. *Int. J. Biol. Macromol.* 160, 26–34. doi:10.1016/j.ijbiomac.2020.05.183
- Jin, W., Li, S., Chen, J., Liu, B., Li, J., Li, X., et al. (2018a). Increased soluble heterologous expression of a rat brain 3-O-sulfotransferase 1 - a key enzyme for heparin biosynthesis. *Protein Expr. Purif.* 151, 23–29. doi:10.1016/j.pep.2018.06.007
- Jin, W., Ren, L., Liu, B., Zhang, Q., and Zhong, W. (2018b). Structural features of sulfated glucuronomannan oligosaccharides and their antioxidant activity. *Mar. Drugs* 16 (9), 291. doi:10.3390/md16090291
- Jin, W., Tang, H., Zhang, J., Wei, B., Sun, J., Zhang, W., et al. (2020d). Structural analysis of a novel sulfated galacto-fuco-xylo-glucurono-mannan from *Sargassum fusiforme* and its anti-lung cancer activity. *Int. J. Biol. Macromol.* 149, 450–458. doi:10.1016/j.ijbiomac.2020.01.275
- Jin, W., Wu, W., Tang, H., Wei, B., Wang, H., Sun, J., et al. (2019). Structure analysis and anti-tumor and anti-angiogenic activities of sulfated galactofucan extracted from *Sargassum thunbergii*. *Mar. Drugs* 17 (1), 52. doi:10.3390/md17010052
- Jin, W., Zhang, W., Liang, H., and Zhang, Q. (2016). The structure-activity relationship between marine algae polysaccharides and anti-complement activity. *Mar. Drugs* 14 (1), 3. doi:10.3390/md14010003
- Jin, W., Zhang, W., Liu, G., Yao, J., Shan, T., Sun, C., et al. (2017). The structure-activity relationship between polysaccharides from *Sargassum thunbergii* and anti-tumor activity. *Int. J. Biol. Macromol.* 105, 686–692. doi:10.1016/j.ijbiomac.2017.07.089
- Jordan, R. E., Favreau, L. V., Braswell, E. H., and Rosenberg, R. D. (1982). Heparin with two binding sites for antithrombin or platelet factor 4. *J. Biol. Chem.* 257 (1), 400–406. doi:10.1016/s0021-9258(19)68378-x
- Liu, H., Zhang, Z., and Linhardt, R. J. (2009). Lessons learned from the contamination of heparin. *Nat. Prod. Rep.* 26 (3), 313–321. doi:10.1039/b819896a
- Loscalzo, J., Melnick, B., and Handin, R. I. (1985). The interaction of platelet factor four and glycosaminoglycans. *Arch. Biochem. Biophys.* 240 (1), 446–455. doi:10.1016/0003-9861(85)90049-9
- Menshova, R. V., Anastuyk, S. D., Ermakova, S. P., Shevchenko, N. M., Isakov, V. I., and Zvyagintseva, T. N. (2015). Structure and anticancer activity *in vitro* of sulfated galactofucan from Brown alga *Alaria angusta*. *Carbohydr. Polym.* 132, 118–125. doi:10.1016/j.carbpol.2015.06.020
- Olson, S. T., Richard, B., Izaguirre, G., Schedin-Weiss, S., and Gettins, P. G. (2010). Molecular mechanisms of antithrombin-heparin regulation of blood clotting proteinases. A paradigm for understanding proteinase regulation by serpin family protein proteinase inhibitors. *Biochimie* 92 (11), 1587–1596. doi:10.1016/j.biochi.2010.05.011
- Pomin, V. H. (2014a). Anticoagulant motifs of marine sulfated glycans. *Glycoconj. J.* 31 (5), 341–344. doi:10.1007/s10719-014-9530-1
- Pomin, V. H. (2012). Fucanomics and galactanomics: Current status in drug discovery, mechanisms of action and role of the well-defined structures. *Biochim. Biophys. Acta* 1820 (12), 1971–1979. doi:10.1016/j.bbagen.2012.08.022
- Pomin, V. H. (2014b). Marine medicinal glycomics. *Front. Cell. Infect. Microbiol.* 4, 5. doi:10.3389/fcimb.2014.00005
- Pomin, V. H. (2015). Marine non-glycosaminoglycan sulfated glycans as potential pharmaceuticals. *Pharm. (Basel)* 8 (4), 848–864. doi:10.3390/ph8040848
- Pomin, V. H., and Mourão, P. A. S. (2014). Specific sulfation and glycosylation-a structural combination for the anticoagulation of marine carbohydrates. *Front. Cell. Infect. Microbiol.* 4, 33. doi:10.3389/fcimb.2014.00033
- Pomin, V. H., Pereira, M. S., Valente, A. P., Tollefsen, D. M., Pavao, M. S., and Mourao, P. A. (2005). Selective cleavage and anticoagulant activity of a sulfated fucan: Stereospecific removal of a 2-sulfate ester from the polysaccharide by mild acid hydrolysis, preparation of oligosaccharides, and heparin cofactor II-dependent anticoagulant activity. *Glycobiology* 15 (4), 369–381. doi:10.1093/glycob/cwi021
- Pomin, V. H., Vignovich, W. P., Gonzales, A. V., Vasconcelos, A. A., and Mulloy, B. (2019). Galactosaminoglycans: Medical applications and drawbacks. *Molecules* 24 (15), 2803. doi:10.3390/molecules24152803
- Rezaie, A. R., and Giri, H. (2020). Anticoagulant and signaling functions of antithrombin. *J. Thromb. Haemost.* 00, 3142–3153. doi:10.1111/jth.15052
- Rodriguez-Jasso, R. M., Mussatto, S. I., Pastrana, L., Aguilera, C. N., and Teixeira, J. A. (2013). Extraction of sulfated polysaccharides by autohydrolysis of Brown seaweed *Fucus vesiculosus*. *J. Appl. Phycol.* 25 (1), 31–39. doi:10.1007/s10811-012-9834-0
- Shevchenko, N. M., Anastuyk, S. D., Menshova, R. V., Vishchuk, O. S., Isakov, V. I., Zadorozhny, P. A., et al. (2015). Further studies on structure of fucoidan from Brown alga *Saccharina gurjanovae*. *Carbohydr. Polym.* 121, 207–216. doi:10.1016/j.carbpol.2014.12.042
- Vasconcelos, A. A., Sucupira, I. D., Guedes, A. L., Queiroz, I. N., Frattani, F. S., Fonseca, R. J., et al. (2018). Anticoagulant and antithrombotic properties of three structurally correlated sea urchin sulfated glycans and their low-molecular-weight derivatives. *Mar. Drugs* 16 (9), 304. doi:10.3390/md16090304
- Wang, J., Zhang, Q., Zhang, Z., Song, H., and Li, P. (2010). Potential antioxidant and anticoagulant capacity of low molecular weight fucoidan fractions extracted from *Laminaria japonica*. *Int. J. Biol. Macromol.* 46 (1), 6–12. doi:10.1016/j.ijbiomac.2009.10.015
- Wu, J. D., Lv, Y. J., Liu, X. X., Zhao, X. L., Jiao, G. L., Tai, W. J., et al. (2015). Structural study of sulfated fuco-oligosaccharide branched glucuronomannan from *Kjellmaniella crassifolia* by ESI-CID-MS/MS. *J. Carbohydr. Chem.* 34 (5), 303–317. doi:10.1080/07328303.2015.1050593
- Zhang, F., Datta, P., Dordick, J. S., and Linhardt, R. J. (2020). Evaluating heparin products for heparin-induced thrombocytopenia using surface plasmon resonance. *J. Pharm. Sci.* 109 (2), 975–980. doi:10.1016/j.xphs.2019.10.040
- Zhang, F., Zheng, L., Cheng, S., Peng, Y., Fu, L., Zhang, X., et al. (2019). Comparison of the interactions of different growth factors and glycosaminoglycans. *Molecules* 24 (18), 3360. doi:10.3390/molecules24183360
- Zhao, J., Kong, Y., Zhang, F., and Linhardt, R. J. (2018). Impact of temperature on heparin and protein interactions. *Biochem. Biophys. Res. Commun.* 7 (2), 241. doi:10.4172/2168-9652.1000241